Provided herein are oronasal formulations including a cannabinoid and N-L-alpha -asparty-L-phenylalamine 1-methyl ester (APM). Also provided are methods of using the formulations.

Provided herein are oronasal formulations including a cannabinoid and N-L-alpha -asparty-L-phenylalamine 1-methyl ester (APM). Also provided are methods of using the formulations.

The present invention relates to a compound of general formula (1) and a preparation method therefor and use of the compound of general formula (1) or isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as an HPK1 inhibitor. The compound of the present invention can be used for preparing a medicament for treating or preventing related diseases mediated by HPK1.

##STR00001##

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

Provided herein are compounds, compositions, and methods useful for reducing, preventing, and/or inhibiting germination of C. difficile spores, including methods for inhibiting C. difficile germination to prevent or treating C. difficile-associated diseases and disorders such as, for example, severe diarrhea and colitis in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided herein are compounds, compositions, and methods useful for reducing, preventing, and/or inhibiting germination of C. difficile spores, including methods for inhibiting C. difficile germination to prevent or treating C. difficile-associated diseases and disorders such as, for example, severe diarrhea and colitis in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided are a method for producing organic material microparticles and a method for modifying organic material microparticles, whereby it becomes possible to improve the crystallinity of organic material microparticles or achieve the crystal transformation of the organic material microparticles while preventing the growth of the organic material microparticles in a solvent. A surfactant is added to a solvent that is capable of partially dissolving organic material microparticles, and then the organic material microparticles are reacted with the solvent. In this manner, it becomes possible to improve the degree of crystallization of the organic material microparticles or achieve the crystal transformation of the organic material microparticles without substantially altering the particle diameters of the organic material microparticles.

Provided are a method for producing organic material microparticles and a method for modifying organic material microparticles, whereby it becomes possible to improve the crystallinity of organic material microparticles or achieve the crystal transformation of the organic material microparticles while preventing the growth of the organic material microparticles in a solvent. A surfactant is added to a solvent that is capable of partially dissolving organic material microparticles, and then the organic material microparticles are reacted with the solvent. In this manner, it becomes possible to improve the degree of crystallization of the organic material microparticles or achieve the crystal transformation of the organic material microparticles without substantially altering the particle diameters of the organic material microparticles.

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.